Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

• Status: RECRUITING
• Trial end date: 2029-01-18

Summary

To find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.

• Phase: PHASE1

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: Bellicum Pharmaceuticals, Inc.
• Treatments: AP 1903 reagent; Cetuximab; Cyclophosphamide; fludarabine; fludarabine phosphate